Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Statins are widely prescribed for hypercholesterolemia but are associated with muscle-related side effects, including rhabdomyolysis.
• Previous research implicated atrogin-1, a key gene in muscle atrophy, in statin-induced muscle damage.
• Statins inhibit numerous biochemical pathways beyond cholesterol synthesis, necessitating investigation into specific mechanisms of muscle toxicity.

Purpose of the Study:

• To identify the specific statin-inhibited pathways responsible for atrogin-1 expression and subsequent muscle damage.
• To elucidate the molecular mechanisms underlying statin-induced myopathy.

Main Methods:

• Utilized cultured mouse myotubes and zebrafish models to study lovastatin effects.
• Investigated the impact of geranylgeranol and farnesol on statin-induced atrogin-1 expression and muscle damage.
• Employed inhibitors of protein geranylgeranylation to assess their role in statin myopathy.

Main Results:

• Lovastatin-induced atrogin-1 expression and muscle damage were prevented by geranylgeranol, but not farnesol, in both cell cultures and zebrafish.
• Inhibitors of protein geranylgeranyl transfer mimicked statin-induced muscle damage and atrogin-1 induction.
• Findings suggest that impaired geranylgeranylation of small GTP-binding proteins contributes to statin myopathy.

Conclusions:

• Statin-induced muscle damage and atrogin-1 expression are linked to the inhibition of protein geranylgeranylation.
• Dysfunction of small GTP-binding proteins, due to impaired geranylgeranyl modification, is implicated in statin myopathy.
• Atrogin-1 may be regulated by novel signaling pathways affected by statin treatment, offering potential therapeutic targets.